Roche drug fails Phase III schizophrenia trials
This article was originally published in Scrip
Bitopertin, Roche's experimental drug for schizophrenia, has failed the first two of six Phase III trials.
You may also be interested in...
Renaissance Capital expects an initial public offering surge in September; Biomedtracker data show financings for COVID-19 programs fell from Q1 to Q2; Revelation will merge with a special purpose acquisition corporation; Ascendis netted $379.3m in a follow-on offering; and Disc Medicine raised $90m in venture capital.
Infographic: A snapshot of executive compensation at the world’s biggest pharmaceutical companies. Explore our interactive dashboard and visualizations comparing remuneration packages with other key company metrics.